Preferential Colonization of Metastases by Oncolytic Vaccinia Virus Strain GLV-1h68 in a Human PC-3 Prostate Cancer Model in Nude Mice

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Donat, Ulrike ^a   Weibel, Stephanie ^a   Hess, Michael ^a   Stritzker, Jochen ^a,b   Härtl, Barbara ^a,d   Sturm, Julia B ^a   Chen, Nanhai G ^b,c   Gentschev, Ivaylo ^a,b   Szalay, Aladar A ^a,b,c,d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b GENELUX CORPORATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Genelux GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD19 ANTIGEN; CD68 ANTIGEN; COLONY STIMULATING FACTOR 1; CXCL3 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; ONCOLYTIC VACCINIA VIRUS GLV 1H68; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE ACTIVATION; BLOOD VESSEL PERMEABILITY; CANCER CELL DESTRUCTION; CELL COUNT; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHOCYTE PROLIFERATION; METASTASIS INHIBITION; MICROBIAL COLONIZATION; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROSTATE CANCER; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TUMOR VASCULARIZATION; UPREGULATION; VIRAL TROPISM; VIRUS COLONIZATION; VIRUS REPLICATION;

ANIMALS; BROMODEOXYURIDINE; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MACROPHAGES; MALE; MICE; MICROSCOPY, FLUORESCENCE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VACCINIA VIRUS;

GIARDIA LAMBLIA VIRUS; MUS; MUS MUSCULUS; VACCINIA VIRUS;

EID: 84866636213     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045942     Document Type: Article

References (32)

1. Sleeman J, Steeg PS, (2010) Cancer metastasis as a therapeutic target. Eur J Cancer 46: 1177-1180.
2. Boyle P, Levin B (2008) The World Cancer Report- the major findings: World Health Organization, Press Release WHO/27/IARC/145.
3. Wynder EL, Mabuchi K, Whitmore WF Jr, (1971) Epidemiology of cancer of the prostate. Cancer 28: 344-360.
4. Apple JS, Paulson DF, Baber C, Putman CE, (1985) Advanced prostatic carcinoma: pulmonary manifestations. Radiology 154: 601-604.
5. Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper BA, et al. (2008) Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 8: 4521-4533.
6. Fidler IJ, (1990) Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50: 6130-6138.
7. Suit HD, (1992) Local control and patient survival. Int J Radiat Oncol Biol Phys 23: 653-660.
8. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE, (2007) Oncolytic viruses in cancer therapy. Cancer Lett 254: 178-216.
9. Zhang Q, Liang C, Yu YA, Chen N, Dandekar T, et al. (2009) The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Genet Genomics 282: 417-435.
10. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, et al. (2007) Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 67: 10038-10046.
11. Gentschev I, Donat U, Hofmann E, Weibel S, Adelfinger M, et al. (2010) Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68. J Biomed Biotechnol 2010: 489759.
12. Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, et al. (2009) Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther 8: 141-151.
13. Burton JB, Priceman SJ, Sung JL, Brakenhielm E, An DS, et al. (2008) Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 68: 7828-7837.
14. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
15. Weibel S, Raab V, Yu YA, Worschech A, Wang E, et al. (2011) Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer 11: 68.
16. Weibel S, Stritzker J, Eck M, Goebel W, Szalay AA, (2008) Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment. Cell Microbiol 10: 1235-1248.
17. Vestweber D, (2007) Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium. Immunol Rev 218: 178-196.
18. Lewenhaupt A, Ekman P, Eneroth P, Nilsson B, (1990) Tumour markers as prognostic aids in prostatic carcinoma. Br J Urol 66: 182-187.
19. Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, et al. (2011) The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers. Mol Ther.
20. Roger W, Williams PL (1973) Gray's anatomy: London: Longman. Angiology (Chapter 6), 588-785 p.
21. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH, (2007) Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 4: e353.
22. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, et al. (2007) Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 15: 1686-1693.
23. Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, et al. (2009) Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics 10: 301.
24. Folkman J, (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
25. Chen Z, Varney ML, Backora MW, Cowan K, Solheim JC, et al. (2005) Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res 65: 9004-9011.
26. Shen Y, Nemunaitis J, (2005) Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther 11: 180-195.
27. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K, (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65: 271-284.
28. Frantz S, Vincent KA, Feron O, Kelly RA, (2005) Innate immunity and angiogenesis. Circ Res 96: 15-26.
29. Cavaillon JM, (1994) Cytokines and macrophages. Biomed Pharmacother 48: 445-453.
30. Sanchez-Puig JM, Sanchez L, Roy G, Blasco R, (2004) Susceptibility of different leukocyte cell types to Vaccinia virus infection. Virol J 1: 10.
31. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, et al. (2009) Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325: 612-616.
32. Ivanov VN, Partridge MA, Huang SX, Hei TK, (2011) Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis. J Cell Biochem 112: 463-475.